The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Goldman Upgrades Booker, Panmure Cuts Meggitt

Wed, 18th May 2016 08:31

LONDON (Alliance News) - The following shares received analyst recommendations Wednesday morning and Tuesday:
----------
FTSE 100
----------
JEFFERIES CUTS STANDARD CHARTERED TARGET TO 330 (400) PENCE - 'UNDERWEIGHT'
----------
GOLDMAN RAISES VODAFONE PRICE TARGET TO 265 (260) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS ITV PRICE TARGET TO 230 (240) PENCE - 'HOLD'
----------
Deutsche Bank Ups Taylor Wimpey Target To 261p From 247p, Keeps Buy
----------
EXANE BNP RAISES ASHTEAD GROUP TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1,050 (900) PENCE
----------
CREDIT SUISSE RAISES TRAVIS PERKINS TARGET TO 2,250 (2,200)P - 'OUTPERFORM'
----------
CREDIT SUISSE RAISES BHP BILLITON PRICE TARGET TO 1050 (900) PENCE - 'OUTPERFORM'
----------
FTSE 250
----------
PANMURE CUTS MEGGITT TO 'SELL' ('HOLD') - TARGET 325 (363) PENCE
----------
LIBERUM RAISES RIGHTMOVE PRICE TARGET TO 5,000 (4,295) PENCE - 'BUY'
----------
Numis Downgrades Marshalls To Add From Buy, Target At 400p
----------
GOLDMAN RAISES BOOKER GROUP TO 'BUY' ('NEUTRAL') - TARGET 198 (171) PENCE
----------
BERENBERG INITIATES JUST EAT WITH 'BUY' - TARGET 530 PENCE
----------
Deutsche Bank Cuts BTG Target To 740p From 755p, Keeps Buy
----------
EXANE BNP CUTS VICTREX PRICE TARGET TO 1,500 (1,650) PENCE - 'NEUTRAL'
----------
SOCGEN RAISES INTERMEDIATE CAPITAL PRICE TARGET TO 725 (660) PENCE - 'BUY'
----------
EXANE BNP CUTS ICAP TO 'NEUTRAL' ('OUTPERFORM') - TARGET 475 (550) PENCE
----------
CREDIT SUISSE CUTS SHAWBROOK PRICE TARGET TO 380 (400) PENCE - 'OUTPERFORM'
----------
MAIN MARKET AND AIM
----------
PANMURE CUTS SCANCELL HOLDINGS PRICE TARGET TO 68 (79) PENCE - 'BUY'
----------
PANMURE CUTS JOHNSTON PRESS PRICE TARGET TO 200 (230) PENCE - 'BUY'
----------
Panmure Cuts Haynes Publishing Target To 150p From 200p, Keeps Buy
----------
PANMURE RAISES HILL & SMITH PRICE TARGET TO 1,100 (950) PENCE - 'BUY'
----------
TRADERS: MERRILL LYNCH REMOVES GENEL ENERGY FROM 'EMERGING EMEA 1' LIST
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
22 Oct 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Oct 2021 20:41

IN BRIEF: Scancell bases new facility at Oxford Science Park

IN BRIEF: Scancell bases new facility at Oxford Science Park

Read more
5 Oct 2021 22:03

IN BRIEF: Scancell doses first subject in Covidity phase one trial

IN BRIEF: Scancell doses first subject in Covidity phase one trial

Read more
26 Aug 2021 12:53

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

Read more
26 Aug 2021 12:38

Scancell gets MHRA approval for Modi-1 clinical trial

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.

Read more
17 Aug 2021 15:32

Scancell chooses needle-free tech for Covid vaccine candidates

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.

Read more
30 Jul 2021 14:24

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
28 Jul 2021 22:00

IN BRIEF: Scancell turns once again to Durrant to lead company

IN BRIEF: Scancell turns once again to Durrant to lead company

Read more
22 Jun 2021 15:21

Scancell makes progress with 'Covidity' trial plans

(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.

Read more
22 Jun 2021 12:14

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

Read more
7 Jun 2021 13:58

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

Read more
7 Jun 2021 10:38

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

Read more
30 Apr 2021 14:30

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

Read more
19 Feb 2021 20:13

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.